Xilio Therapeutics, Inc.
XLO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $121 | $66 | $54 | $62 |
| - Cash | $104 | $122 | $89 | $55 |
| + Debt | $7 | $8 | $8 | $8 |
| Enterprise Value | $25 | -$48 | -$27 | $15 |
| Revenue | $19 | $8 | $3 | $2 |
| % Growth | 135.8% | 175.9% | 70% | – |
| Gross Profit | $19 | -$7 | $3 | $2 |
| % Margin | 98.2% | -89.6% | 100% | 100% |
| EBITDA | -$16 | -$14 | -$13 | -$13 |
| % Margin | -83.6% | -173% | -455.8% | -768.8% |
| Net Income | -$16 | -$16 | -$13 | -$13 |
| % Margin | -85.4% | -196% | -452.7% | -759.5% |
| EPS Diluted | -0.11 | -0.16 | -0.18 | -0.2 |
| % Growth | 31.3% | 11.1% | 10% | – |
| Operating Cash Flow | -$17 | -$14 | $29 | -$14 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$17 | -$15 | $29 | -$14 |